Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup
A little more than a year ago Sanofi $SNY handed ImmunoGen a $30 million payment to gain exclusive development rights to a slate of experimental cancer drugs in the pipeline, including the Phase II drug SAR566658, an ADC targeting CA6 spotlighted in the deal that was in development for triple negative breast cancer.
Today, it’s history.
The French pharma giant wrote the drug off, saying that it was ending development efforts for the that drug as well as a TB vaccine program.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.